PB1903: TRIAL IN PROGRESS: A MULTICENTER, OPEN-LABEL, PHASE IB/II STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)

• N. Hijiya,
• S. Kapoor,
• M. Hoch,
• L. Descamps,
• M. A. Bayar,
• N. Ramscar

Affiliations

N. Hijiya

1 Columbia University Medical Center, New York

S. Kapoor

2 Novartis Pharmaceuticals Corporation, East Hanover, United States of America

M. Hoch

3 Novartis Institute for BioMedical Research, Basel, Switzerland

L. Descamps

4 Novartis Pharma SAS, Rueil-Malmaison, France

M. A. Bayar

4 Novartis Pharma SAS, Rueil-Malmaison, France

N. Ramscar

5 Novartis Pharma AG, Basel, Switzerland